title: A case of abatacept associated neutrophilic dermatosis and a review of the literature.
abstract: Abatacept is a novel biological agent that dampens the immune response by blocking the co-stimulation of T-cells, thus downregulating T-cell activation. It is currently approved for the treatment of rheumatoid arthritis (RA). The group of novel immunomodulatory agents, referred to as biologics, have now been used extensively, with established safety and side-effect profiles. There are, however, increasing reports of adverse paradoxical reactions, most notably resulting from anti-tumour necrosis factor (TNF) therapy. While cutaneous adverse reactions to abatacept are rare, there are a few reports of such paradoxical reactions. We report a case of an idiosyncratic paradoxical neutrophilic dermatosis associated with the use of abatacept.
authors.affiliation: Sir Charles Gairdner Hospital, Nedlands, Western Australia.
authors.forename: Shevya Manjri
authors.initials: SM
authors.lastname: Tiwari
authors.forename: Benjamin A
authors.initials: BA
authors.lastname: Wood
authors.forename: Theresa
authors.initials: T
authors.lastname: Skender-Kalnenas
authors.forename: Nicola
authors.initials: N
authors.lastname: Cook
mesh_terms: D000069594:Abatacept / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009504:Neutrophils
chemical_list: D018501:Antirheumatic Agents; D000069594:Abatacept
keywords: Sweet's syndrome; abatacept; biologics; neutrophilic dermatosis; paradoxical reaction; rheumatoid neutrophilic dermatosis